Clinically meaningful worsening ( progression ) of LCVA was noted in substantial proportions of patients in AFFIRM and was prevalent even among those without EDSS progression over 2 years ( 21.9 % with LCVA progression at 2.5 % contrast ; 26.2 % at 1.25 % contrast ) .